Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28995150 | 0.94 | OPRM1 (0.33) | OPRM1 | |
| SCHEMBL638552 | 0.89 | OPRM1 (0.39) | OPRM1 | |
| SCHEMBL1930365 | 0.86 | OPRM1 (0.35) | OPRM1 | |
| SCHEMBL2553994 | 0.86 | OPRM1 (0.35) | OPRM1 | |
| SCHEMBL375919 | 0.81 | — | — | |
| SCHEMBL56523 | 0.81 | — | — | |
| SCHEMBL6064038 | 0.78 | LMNA (0.32) | — | |
| SCHEMBL9945699 | 0.77 | LMNA (0.32) | — | |
| SCHEMBL728369 | 0.77 | — | — | |
| SCHEMBL28670104 | 0.76 | OPRM1 (0.46) | OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570899-B2 | Bright silver based quaternary nanostructures | SHOEI CHEMICAL INC. (JP) | 2026-03-10 | — | — | US | disclosed |
| US-20240263069-A1 | BRIGHT SILVER BASED QUATERNARY NANOSTRUCTURES | SHOEI CHEMICAL INC. (JP) | 2024-08-08 | — | — | US | disclosed |
| US-11970646-B2 | Bright silver based quaternary nanostructures | SHOEI CHEMICAL INC. (JP) | 2024-04-30 | — | — | US | disclosed |
| EP-3816247-B1 | CURING MIXTURE | EVONIK OPERATIONS GMBH (DE) | 2022-12-07 | — | — | EP | disclosed |
| US-20220228057-A1 | BRIGHT SILVER BASED QUATERNARY NANOSTRUCTURES | NANOSYS, INC. (US) | 2022-07-21 | — | — | US | disclosed |
| US-11254819-B2 | Curing agent mixture | EVONIK OPERATIONS GMBH (DE) | 2022-02-22 | — | — | US | disclosed |
| EP-2994495-B2 | CROSSLINKING OF IPMS ADDUCTS AND AMINOSILANES | EVONIK OPERATIONS GMBH (DE) | 2021-09-22 | — | — | EP | disclosed |
| EP-3816247-A1 | CURING MIXTURE | Evonik Operations GmbH (DE) | 2021-05-05 | — | — | EP | disclosed |
| US-20210122921-A1 | Curing agent mixture | EVONIK OPERATIONS GMBH (DE) | 2021-04-29 | — | — | US | disclosed |
| US-10927294-B2 | Bright silver based quaternary nanostructures | NANOSYS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20160108280-A1 | CROSSLINKING OF IPMS ADDUCTS WITH AMINOSILANES | EVONIK DEGUSSA GMBH (DE) | 2016-04-21 | — | — | US | disclosed |
| EP-2994495-A1 | CROSSLINKING OF IPMS ADDUCTS AND AMINOSILANES | Evonik Industries AG (DE) | 2016-03-16 | — | — | EP | disclosed |
| US-9266825-B2 | Copolymers of isocyanatoalkyltrialkoxysilanes and urethanediols | EVONIK DEGUSSA GMBH (DE) | 2016-02-23 | — | — | US | disclosed |
| EP-2905296-B1 | Copolymers made of isocyanatoalkyltrialkoxysilanes and urethane diols | EVONIK DEGUSSA GMBH (DE) | 2015-12-23 | — | — | EP | disclosed |
| US-20150225337-A1 | COPOLYMERS OF ISOCYANATOALKYLTRIALKOXYSILANES AND URETHANEDIOLS | EVONIK INDUSTRIES AG (DE) | 2015-08-13 | — | — | US | disclosed |
| EP-2905296-A1 | Copolymers made of isocyanatoalkyltrialkoxysilanes and urethane diols | Evonik Degussa GmbH (DE) | 2015-08-12 | — | — | EP | disclosed |
| EP-2552925-B1 | PROCESS FOR THE PREPARATION OF SILICON CONTAINING AZODICARBAMIDES | EVONIK DEGUSSA GMBH (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-8664370-B2 | Process for preparing silicon-containing azodicarbamides | EVONIK DEGUSSA GMBH (DE) | 2014-03-04 | — | — | US | disclosed |
| US-20130012691-A1 | Process for Preparing Silicon-Containing Azodicarbamides | EVONIK OPERATIONS GMBH (DE) | 2013-01-10 | — | — | US | disclosed |
| WO-2011120792-A1 | PROCESS FOR PREPARING SILICON-CONTAINING AZODICARBAMIDES | EVONIK DEGUSSA GMBH (DE) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570899-B2 | Bright silver based quaternary nanostructures | LGALS3, ANXA3, ATXN2L | OPRM1 2012/4885 |
| US-20130012691-A1 | Process for Preparing Silicon-Containing Azodicarbamides | C1R, CA9, CCNB3 | OPRM1 3084/4885 |
| US-20150225337-A1 | COPOLYMERS OF ISOCYANATOALKYLTRIALKOXYSILANES AND URETHANEDIOLS | ACMSD, OR10J3, CCND2 | OPRM1 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.